Search

Displaying results 4711 - 4720 of 10000 in total
  1. Drug

    Oxyphenisatin acetate

    go.drugbank.com/drugs/DB14627
    ApprovedWithdrawn

    Oxyphenisatin acetate is the pro-drug of [oxyphenisatin] (3,3-bis(4-hydroxyphenyl)-1H-indol-2-one). The FDA withdrew its approval for the use of oxyphenisatin acetate due to safety reasons.[L43942]

  2. Drug

    Rheinanthrone

    go.drugbank.com/drugs/DB13175
    Experimental

    Rheinanthrone is the active metabolite of senna glycoside [DB11365] known for its laxative effect [A19235]. It is commonly produced by plants of the Rheum species [L772].

  3. Drug

    Guanadrel

    go.drugbank.com/drugs/DB00226
    Approved

    Guanadrel is an antihypertensive agent and postganglionic adrenergic blocking agent.

  4. Drug

    Brentuximab

    go.drugbank.com/drugs/DB05471
    Investigational

    SGN-30 received orphan drug designation from the FDA in July 2003 for Hodgkin lymphoma and in February 2004 for T-cell lymphomas. … SGN-30 has been shown to induce direct anti-cancer activity towards tumor cells expressing CD30 and is undergoing phase II trials for cancer therapy.

  5. Drug

    Cambinol

    go.drugbank.com/drugs/DB15493
    Experimental

    Cambinol is a beta-naphtol derivative that inhibits NAD-dependant deacetylases to reduce cell survival under stress. This activity is currently being investigated for its use as a cancer treatment.

  6. Drug

    Chloric acid

    go.drugbank.com/drugs/DB14150
    Approved

    Categories: Compounds used in a research, industrial, or household setting
  7. Drug

    IMM101

    go.drugbank.com/drugs/DB15851
    Experimental

    It has shown to be safe and well tolerated to complement conventional cancer therapy for patients with melanoma and pancreatic ductal adenocarcinoma [PMID: 21930686; PMID: 30107850; PMID: 27599039]. … As of July 2020, researchers from the Ottawa Hospital and Queen’s University, in partnership with the Canadian Cancer Society-funded Canadian Cancer Trials Group (CCTG), are conducting a trial in over

  8. Drug

    Recombinant alpha 1-antitrypsin

    go.drugbank.com/drugs/DB05481
    Investigational

    The proteinase/antiproteinase balance is believed to be important for maintaining healthy skin. The rAAT topical gel (Dermolastin™) is indicated for patients with atopic dermatitis and psoriasis. … for a increased manufacturing.

  9. Drug

    Ad5-nCoV

    go.drugbank.com/drugs/DB15655
    Investigational

    Ad5-nCoV is a recombinant adenovirus type-5 vector (Ad5) vaccine currently being investigated for prophylaxis against SARS-CoV-2. … The study will evaluate antibody response in healthy patients between the ages of 18 and 60 who will receive one of three study doses, with follow-up taking place at weeks 2 and 4 and months 3 and 6 post-vaccination

    Categories: Experimental Unapproved Treatments for COVID-19
  10. Drug

    Dirucotide

    go.drugbank.com/drugs/DB04921
    Investigational

    Dirucotide is a synthetically prepared peptide. In particular, the sequence prepared is a 17 amino acid chain that is identical to a section of myelin basic protein (MBP) that is found in humans. … Dirucotide has been developed for the treatment of multiple sclerosis (MS). Developed at the University of Alberta, dirucotide is being investigated by BioMS Medical Corp.